To assess the clinical relevance of DHODH upregulation by MYCN, we analyzed gene expression profiling data from three independent neuroblastoma patient cohorts (SEQC, NRC, and VERSTEEG) [22–24]. This evidence concerns the gene MYCN and neuroblastoma.